|Bid||10.08 x 36100|
|Ask||10.15 x 21500|
|Day's range||10.02 - 10.62|
|52-week range||9.45 - 15.60|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||72.07|
|Forward dividend & yield||0.48 (4.93%)|
|Ex-dividend date||23 May 2022|
|1y target est||N/A|
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.